Quince Therapeutics (QNCX) Expected to Announce Quarterly Earnings on Monday

Quince Therapeutics (NASDAQ:QNCX) will likely be posting its quarterly earnings results on Monday, March 24th. Analysts expect Quince Therapeutics to post earnings of ($0.18) per share for the quarter.

Quince Therapeutics Trading Up 0.7 %

Shares of Quince Therapeutics stock opened at $1.38 on Friday. The firm has a market capitalization of $60.72 million, a PE ratio of -1.11 and a beta of 0.71. Quince Therapeutics has a twelve month low of $0.51 and a twelve month high of $2.45. The firm’s 50-day moving average price is $1.50 and its 200 day moving average price is $1.43. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of Quince Therapeutics in a research note on Wednesday, February 5th. Brookline Capital Management assumed coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Quince Therapeutics presently has a consensus rating of “Buy” and an average target price of $9.50.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.